Synlogic, Inc. announced that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). Pursuant to the terms of the research collaboration agreement, Synlogic and Roche collaborated to develop a Synthetic Biotic to address an undisclosed novel target in IBD. Roche has the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the product candidate.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -1.16% | -7.10% | -55.84% |
Mar. 21 | Synlogic, Inc. Announces Board Changes | CI |
Mar. 21 | North American Morning Briefing : Investors -2- | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
234.8 CHF | +3.21% | +4.31% | 203B | ||
1.7 USD | -1.16% | -7.10% | 20.03M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.84% | 20.03M | |
+33.35% | 49.46B | |
+1.76% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.30% | 18.64B | |
+7.83% | 13.16B | |
+29.52% | 12.55B | |
+24.25% | 12.1B |
- Stock Market
- Equities
- SYBX Stock
- News Synlogic, Inc.
- Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration